Please assess the completion status of the following clinical trial:

Trial Title: Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or females - 18 years or older~* Been convicted of drinking driving and allocated to either the education or the treatment group of the BOT program~* Meet criteria for alcohol dependence using the SCID-IV~* Consume more than 14 drinks (female) or 21 drinks (male) per week with a minimum of 2 heavy drinking days (≥ 4 drinks for females and ≥ 5 drinks for males) during a consecutive 30-day period within the 90 days prior to the baseline evaluation~* Willing to receive pharmacotherapy for their alcohol dependence~* Seeking abstinence from alcohol as their main goal~Exclusion Criteria:~* History of other substance use (other than nicotine or cannabis) by DSM-IV criteria in the last 90 days (6 months for opiate abuse)~* Positive urine drug screen~* Psychiatric disorder requiring medication~* Unstable medical condition requiring immediate investigation or treatment~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Naltrexone (Type: EXPERIMENTAL): Drug: Naltrexone 50 mg/day for 24 weeks.All participants will receive medical intervention in the form of medical management (MM) which will be delovered by a trained health care professional.
- Control (Type: PLACEBO_COMPARATOR): Drug: Control Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.

Based on this trial design, predict the completion outcome and termination type (if applicable).